基于网络药理学预测黄芪抗肝癌的有效成分及其潜在靶点

摘要

OBJECTIVE: To probe into the effective components and potential targets of Astragalus in anti-liver cancer based on network pharmacology. METHODS: By establishing a dataset of the drug target of Astragalus and liver cancer disease target dataset, the "ingredients-target-disease" interactive network of Astragalus in treatment of liver cancer was constructed. The active ingredients and potential effects of Astragalus to anti-liver cancer were predicted by visual analysis. RESULTS: Astragalus may act on protein targets such as interleukin-6, cell tumor antigen p53, CYP3 A4, mitogen-activated protein kinase 14, cyclin A2, and CYP2 A6 directly and simultaneously regulating nucleotide-binding oligomerization domain-like receptor signaling pathways, TNF signaling pathways, sphingolipid signaling pathways and other pathways to achieve their therapeutic goals. CONCLUSIONS: This study preliminarily revealed the potential regulatory network of Astragalus against liver cance through network pharmacology, which provided a reference for the follow-up experimental research and clinical application of Astragalus.%目的:基于网络药理学,初步探讨预测黄芪抗肝癌的有效成分及潜在作用靶点.方法:通过建立黄芪药物靶点数据集、肝癌疾病靶点数据集,构建黄芪抗肝癌的"成分-靶点-疾病"交互网络图,并通过可视化分析,预测黄芪抗肝癌的有效成分及潜在作用靶点.结果:黄芪可能是通过直接作用于白细胞介素6、细胞肿瘤抗原p53、肝药酶CYP3A4、丝裂原活化蛋白激酶14、细胞周期素A2及肝药酶CYP2A6等蛋白靶点,并通过调节核苷酸结合寡聚化结构域样受体信号通路、肿瘤坏死因子信号通路及鞘脂信号通路等多条通路达到其治疗目的.结论:本研究通过网络药理学初步揭示了黄芪抗肝癌的潜在调控网络,为其后续实验研究及临床应用提供了参考.